InvestorsHub Logo

MinnieM

05/21/17 7:17 PM

#182761 RE: Drakon 642 #182757

Brilacidin is an amazing drug in it's antibacterial and anti inflammatory uses.

It's usage in the prevention of severe Oral Mucositis is particularly exciting to me.

http://www.cellceutix.com/press-release/2017/4/8/cellceutix-ceo-discusses-brilacidin-following-interim-trial-results-exceeding-expectations-for-treating-oral-mucositis-and-inflammatory-bowel-disease

According to the preliminary interim results from the trial, only 2 of 9 patients (22.2%) on Brilacidin-OM therapy developed severe OM, defined as Grade 3 or Grade 4 on the World Health Organization (WHO) OM Grading Scale. Patients in the placebo-treated control arm developed severe OM at a much higher rate, with 7 of 10 patients (70%) progressing to that condition. There are now an additional 11 patients active in the trial and more are added weekly.











In Reply to 'Drakon 642'
New blog on Brilacidin on $ctix site:

http://www.cellceutix.com/new-blog/2017/6/5/brilacidins-potential-application-in-dermatology





mdphd2008

05/21/17 11:00 PM

#182769 RE: Drakon 642 #182757

It certainly is great having a board certified dermatologist with an extensive research background as part of the management/leadership of CTIX.

TheDane

05/22/17 7:26 AM

#182771 RE: Drakon 642 #182757

Another good article regarding Brilacidin and its potential. I like the way they're using the website.